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Abstract
Aims/hypothesis Rosiglitazone, an insulin sensitiser, not
only improves insulin sensitivity but also enhances insulin
secretory capacity by ameliorating gluco- and lipotoxicity
in beta cells. Rosiglitazone can stimulate insulin secretion
at basal and high glucose levels via a phosphatidylinositol
3-kinase (PI3K)-dependent pathway. We hypothesised that
regulation of phosphorylation of the ATP-sensitive potas-
sium (KATP) channel might serve as a key step in the regu-
lation of insulin secretion.
Methods Insulin secretory responses were studied in an
isolated pancreas perfusion system, cultured rat islets and
MIN6 and RINm5F beta cells. Signal transduction path-
ways downstream of PI3K were explored to link rosiglita-
zone to KATP channel conductance with patch clamp
techniques and insulin secretion measured by ELISA.
Results Rosiglitazone stimulated AMP-activated protein
kinase (AMPK) activity and induced inhibition of the KATP
channel conductance in islet beta cells; both effects were
blocked by the PI3K inhibitor LY294002. Following
stimulation of AMPK by 5-aminoimidazole-4-carboxamide
ribonucleoside (AICAR), a pharmacological activator, both
AICAR-stimulated insulin secretion and inhibition of KATP
channel conductance were unaffected by LY294002, indi-
cating that AMPK activation occurs at a site downstream of
PI3K activity. The serine residue at amino acid position 385
of Kir6.2 was found to be the substrate phosphorylation site
of AMPK when activated by rosiglitazone or AICAR.
Conclusions/interpretation Our data indicate that PI3K-
dependent activation of AMPK is required for rosiglitazone-
stimulated insulin secretion in pancreatic beta cells.
Phosphorylation of the Ser385 residue of the Kir6.2 subunit
of the KATP channel by AMPK may play a role in insulin
secretion.
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Kir6.2 Inwardly rectifying K+ channel subunit
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Type 2 diabetes is characterised by peripheral insulin
resistance, impaired insulin secretion and enhanced hepatic
glucose production [1]. Pancreatic beta cell function has
been shown to deteriorate as the duration of diabetes
increases despite the use of existing therapies, as demon-
strated in the UK Prospective Diabetes Study [2]. The
thiazolidinediones, on the other hand, are a new class of
glucose-lowering agent targeted at peroxisome proliferator-
activated receptor γ (PPARγ) [3] and have a beneficial
effect on beta cell functions [4, 5]. This beneficial effect on
beta cell function is partly mediated by alleviating gluco-
and lipotoxicity [5, 6] and partly by a protective effect
against apoptosis [5–11] of beta cells. In one human study,
it was reported that glucose-entrained high-frequency
insulin pulsatility in response to an oscillatory glucose
infusion improved after treatment with rosiglitazone for
3 months, despite the absence of a change in beta cell
secretory capacity [12].
Few studies have addressed the acute action of thiazo-
lidinediones on beta cell function. In one early study [4], it
was demonstrated that short-term treatment (10 or 60 min)
with troglitazone induced insulin secretion. This insulin
secretory response was accompanied by an increase in
cytoplasmic free Ca2+ concentrations in both isolated islets
and in HIT insulin-secreting beta cells. Furthermore,
thiazolidinediones can inhibit ATP-sensitive potassium
(KATP) channels in CRI-G1 insulin-secreting cells [13,14],
although the mechanism underlying this action has not been
well studied. We have previously reported that rosiglita-
zone, in addition to its stimulatory effect on insulin
secretion at a basal glucose concentration, also enhanced
the first and second phases of insulin secretion at a high
glucose concentration [15]. This stimulating effect of
rosiglitazone is dependent on phosphatidylinositol 3-kinase
(PI3K) activity [15]. However, the mechanism by which
PI3K activation causes an insulin secretory response in beta
cells remains unknown.
Recently, 5-aminoimidazole-4-carboxamide ribonucleo-
side (AICAR), an allosteric activator of AMP-dependent
protein kinase (AMPK), has been shown to stimulate
insulin release in both isolated islets and perfused pancre-
atic beta cells [16, 17]. The effects of AICAR on insulin
secretion are mediated by both KATP channel-dependent
and -independent pathways [18]. KATP channels are hetero-
octamers which are composed of four sulfonylurea receptor
(SUR1) subunits and four inwardly rectifying K+ channel
(Kir6.2) subunits [19], which are regulated by allosteric
activation with various nucleotides [20]. KATP channel
activity can also be regulated by phosphorylation events of
the constituent proteins, such as phosphorylation of Ser372
of the Kir6.2 subunit and Ser1571 of the SUR1 subunit by
protein kinase A [21] and phosphorylation of the Thr180
residue of the Kir6.2 subunit by protein kinase C [22]. In
this study, we investigated the function of AMPK in the
rosiglitazone-potentiated insulin secretory response, and the
potential site of phosphorylation of the Kir6.2 subunit.
Methods
Chemicals All chemicals were purchased from Sigma
Chemical (St Louis, MO, USA), except for rosiglitazone
(BRL49653), LY294002 and compound C, which were
provided by GlaxoSmithKline Pharmaceuticals (Brentford,
UK), Eli Lilly (Indianapolis, IN, USA) and Merck Research
Laboratories (Rahway, NJ, USA), respectively. Bis-(1,3-
dibutylbarbituric acid)pentamethine oxonol [DiBAC4(5)]
was purchased from Invitrogen (Carlsbad, CA, USA).
Experimental animals Male Sprague–Dawley rats weigh-
ing 250–350 g, obtained from the Animal Center of the
National Science Council of the Republic of China, were
used in these experiments. Animal studies were approved
by the institutional review board. The principles of
laboratory animal care outlined in NIH publication No.
85–23 (revised 1985) were followed in all experiments.
Pancreatic perfusion In situ rat pancreatic perfusion was
performed using an open system at 37°C, as described
previously [15, 23]. After a 10 min baseline perfusion,
insulin secretory responses to AICAR (50 μmol/l) in the
presence of either 5.5 or 10 mmol/l glucose were assessed
as indicated in the experimental procedures. Effluent fluid
was collected from the portal vein cannula at intervals of
1 min for either 50 or 140 min. The collected effluent was
kept at 4°C and subsequently assayed for insulin, as
described previously [15, 24].
Rat islet isolation and culture Rat pancreas islet cells were
isolated from male Sprague–Dawley rats weighing 250–
300 g by collagenase digestion, as described previously [25].
Islet cells were cultured at 37°C, 5% CO2, pH 7.4, in RPMI
1640 containing 10% fetal bovine serum, 10 mmol/l glucose,
180 μmol/l penicillin and 68.6 μmol/l streptomycin and used
2–3 days after isolation.
Cell line and cell culture MIN6 cells, kindly provided by
S. Seino (Kobe University, Japan), were used between
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passages 15 and 25 and grown in DMEM containing 10%
(vol/vol) fetal calf serum at 37°C with 5% CO2. RINm5F
cells were used between passage 15 and 25 and grown in
RPMI containing 10% (vol./vol.) fetal calf serum at 37°C
with 5% CO2.
MIN6 or RINm5F cells were seeded and incubated for
about 24 h before the experiment. Next, the previous
medium was removed and replaced with DMEM (MIN6) or
RPMI (RINm5F) containing 0.2% BSA at 37°C for 2 h.
This medium was then removed and replaced with KRB
buffer, 5 mmol/l sodium bicarbonate and 0.2% (wt/vol.)
BSA containing either 3.3 or 16.7 mmol/l glucose with or
without drug treatment.
Cell extraction and assay of AMPK activity Rat islets,
MIN6 cells or RINm5F cells were lysed and immunopre-
cipitated with anti-AMPK α subunit antibody (Cell
Signaling Technology, Beverly, MA, USA) as described
previously [26]. The AMPK activity in the immunopre-
cipitate was assessed as a function of phosphorylation of a
SAMS-containing peptide (HMRSAMSGLHLVKRR) [26]
or an FSIS-containing peptide (KFSISPDSLS) (amino acids
381–390 of the Kir6.2 subunit of the KATP channel).
Antibodies, immunoprecipitation and western blot analyses
Polyclonal antibodies against Kir6.2 were generated by
immunising rabbits with KLH-conjugated APSEGTAEPC.
The antibody was purified by peptide-specific affinity
column chromatography. In addition, mouse monoclonal
anti-phosphoserine385 of the Kir6.2 antibody (clone 6B3)
was produced by immunising BALB/c mice with KLH-
conjugated PKFSI(S*)PDSLC. The antibodies were pro-
duced in ascites and purified with a protein G column.
Anti-AMPK α subunit and anti-AMPK phospho-
threonine172 antibodies were purchased from Cell Signaling
Technology.
Equal amounts (1 mg) of cell lysates from rat islets,
MIN6 cells or RINm5F cells were immunoprecipitated with
anti-Kir6.2 antibody and then analysed by western blotting
with either rabbit anti-Kir6.2 antibody or 6B3 monoclonal
anti-phosphoserine385 Kir6.2 antibody [27]. For direct
immunoblotting, equal amounts (50 μg) of MIN6 or
RINm5F cell lysate were analysed by western blotting with
an anti-AMPK α subunit antibody and an anti-AMPK
phosphothreonine172 antibody (Cell Signaling Technology).
Measurement of KATP current The KATP current was
recorded by a whole-cell voltage clamp technique at room
temperature (∼25°C) in single islets 10–15 μm in diameter.
The whole-cell patch clamp technique was used to record
ionic currents with a patch clamp amplifier (WPC-100; ESF
Electronic, Goettingen, Germany). Heat-polished glass
electrodes, with tip resistances between 2 and 5 MΩ when
filled with pipette internal solution, were used. Signals were
acquired with a Digidata 1322 analogue-to-digital interface
controlled by pClamp software (Axon Instruments, Foster
City, CA, USA). Recordings were low-pass filtered at
10 kHz and stored for further analysis. The pipette internal
solution contained 130 mmol/l potassium aspartate,
10 mmol/l KCl, 10 mmol/l NaCl, 2 mmol/l MgCl2,
10 mmol/l HEPES, 0.3 mmol/l ATP, 0.3 mmol/l ADP,
11 mmol/l EGTA and 1 mmol/l CaCl2, pH 7.2. The bath
KRP solution contained 109 mmol/l NaCl, 4.6 mmol/l KCl,
0.4 mmol/l KH2PO4, 1.15 mmol/l NaH2PO4, 1.1 mmol/l
MgCl2, 3.2 mmol/l CaCl2, 10 mmol/l HEPES and
3.3 mmol/l glucose, pH 7.4. Currents at −40 mV were
recorded continuously in response to the different treat-
ments, and ramp currents were elicited from −80 to 0 mV
with slope 80 V/s to establish a current–voltage relationship
at the time points indicated in the results. The current of the
KATP channel (IKATP) was gradually activated and devel-
oped to a steady amplitude within 5 min after intracellular
dialysis under the condition of a low ATP/ADP ratio; the
developed current was stable and could be kept at the same
level (less than 5% run-down) for 20 min in the control
condition.
Silencing of α subunit of AMPK in RINm5F cells RINm5F
cells were cultured in RPMI containing 10% fetal calf
serum without antibiotics until 50% confluence. Then,
scrambled short interfering RNA (siRNA; Stealth RNAi
negative control with low GC content; Invitrogen) or
siRNA of the α1 subunit of AMPK (5′-UUAAGGCUU
CAUCAUCAAUCAUGGU-3′, 5′-ACCAUGAUUGAU
GAUGA AGCCUUAA-3′; Invitrogen) was transfected into
RINm5F cells using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions.
Exchanging S385 for Ala in human Kir6.2 subunit A
pCMV6c-hKir6.2 (human Kir6.2), kindly provided by
S. Seino (Kobe University, Japan), was used to construct
wild-type pCMS-EGFP-hKir6.2. The Ser385Ala mutant
type of Kir6.2 was then generated using the QuickChange
II site-directed mutagenesis kit (Stratagene, La Jolla, CA,
USA) to replace serine at the 385th amino acid with alanine.
The forward primer was 5′-TTCAGCATCGCTCCAGA
TTCCCTGTCCTGA-3′ and the reverse primer was 5′-
TCAGGACAGGGAATCTGGAGCGATGCTGAA-3′. The
wild-type or Ser385Ala mutant plasmid was transfected
into RINm5F cells using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions.
Flow cytometric measurement of the change in membrane
potential Flow cytometric measurement of the change in
membrane potential in response to rosiglitazone or AICAR
in RINm5F cells transfected with wild-type or Ser385Ala
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mutant Kir6.2 subunit was carried out using a FACSCalibur
cytometer (Becton Dickinson, Mountain View, CA, USA).
RINm5F cells were resuspended in 1 ml KRB solution
containing 3.3 mmol/l glucose and 400 nmol/l DiSBAC4(5)
with or without drug treatment. DiSBAC4(5) is a slow-
response, potential-sensitive probe that can enter depolarised
cells, where it binds to intracellular proteins or membranes
and exhibits enhanced fluorescence and a red spectral shift
(excitation maximum 590 nm, emission maximum 616 nm).
Emission was detected through a 515–545 nm broadband
interference filter for EGFP (FL1) and 564–606 nm for
DiBAC4(5) (FL2). Cytofluorimetric data were analysed using
Cellquest software (Becton Dickinson). The geometric means
of the FL2 fluorescence histograms were calculated from the
EGFP-positive cells, which were gated by FL1 at the region in
the presence of increased FL1 intensity, as indicated in Fig. 6,
on the basis of 2×104 cells. For cells in the control group
(without transfection), the FL2 geometric mean was calcu-
lated directly from 2×104 cells.
Data expression and statistical analysis Effluent insulin
concentration was recorded as the percentage of the
baseline insulin level (calculated as the mean of 12 baseline
values), and the data are presented as mean±SE. ANOVA
was used to determine the statistical significance of
treatment and time data. Tukey’s honestly significant
difference post hoc test was used to determine the statistical
significance of differences between treatments for which
the ANOVA analysis showed significance. Statistical
significance was accepted at p<0.05. The statistical
significances of differences in other data between or
among different experimental conditions were analysed
with Student’s t test, the paired t test, ANOVA or non-
parametric analysis, using the Statistical Package for the
Social Sciences version 8 (SPSS, Chicago, IL, USA).
Results
Rosiglitazone-stimulated AMPK phosphorylation depends
on PI3K activity in MIN6 beta cells Rosiglitazone sig-
nificantly increased phosphorylation of the Thr172 of the
α subunit of AMPK in MIN6 beta cells in a concentration-
and time-dependent manner (Electronic supplementary
material [ESM] Fig. 1a, b). This effect was independent of
glucose concentration. LY294002, a PI3K inhibitor, markedly
inhibited both rosiglitazone-induced AMPK phosphorylation
(Fig. 1a) and its kinase activity (Fig. 1b). These effects were
observed at both low and high glucose concentrations.
Pharmacological activator of AMPK stimulates insulin
secretion in isolated rat pancreas perfusion and in cultured
MIN6 beta cells At basal glucose concentration (5.5 mmol/l),
perfusion with 50 μmol/l AICAR resulted in a 45%
increase in insulin release within 2–3 min in the isolated
rat pancreas. Insulin secretion increased progressively as
perfusion continued, reached an increase of ∼100% at
30 min, and then declined gradually after AICAR was
removed (Fig. 2a). Consistently, AMPK activator enhanced
both first- and second-phase insulin secretion during
perfusion with a high glucose concentration (10 mmol/l)
(Fig. 2b).
In MIN6 cells, AICAR increased insulin secretory
responses by 35% and 47% at low and high glucose
concentrations (3.3 and 16.7 mmol/l), respectively (Fig. 2c).
The stimulatory effect of AICAR on insulin secretion was
Fig. 1 Effect of PI3K activity on rosiglitazone-stimulated AMPK
activation. a Western blot with anti-AMPK and anti-Thr172-phospho-
AMPK in the absence or presence of rosiglitazone (RSG; 4.5 µmol/l)
and/or LY294002 (3.9 µmol/l) in low (3.3 mmol/l) and high
(16.7 mmol/l) glucose (Glu) in MIN6 cells. pAMPK/AMPK density
relative to that in glucose 3.3 mmol/l is shown below (n=3). White
columns, control; black columns, rosiglitazone 4.5 µmol/l; light
grey columns, rosiglitazone 4.5 µmol/l and LY294002 3.9 µmol/l.
*p<0.05, non-parametric analysis. b AMPK enzyme activity in the
absence or presence of rosiglitazone (4.5 µmol/l) and/or LY294002
(3.9 µmol/l) in low (3.3 mmol/l) and high (16.7 mmol/l) glucose in
MIN6 cells. Data are shown as relative AMPK activity (mean % and
SE [bar]) compared with that in glucose at 3.3 mmol/l (100% as
referent) (n=4). The experimental condition for each column is the
same as that for the corresponding column in a. *p<0.05. c Insulin
secretory response in the absence or presence of rosiglitazone
(4.5 µmol/l) and/or LY294002 (3.9 µmol/l) and wortmannin
(50 nmol/l) in low (3.3 mmol/l) and high (16.7 mmol/l) glucose in
MIN6 cells. Data are relative insulin responses (mean % and SE [bar])
compared with that in glucose 3.3 mmol/l (100% as referent) (n=4).
White columns, control; black columns, rosiglitazone 4.5 µmol/l; light
grey columns, rosiglitazone 4.5 µmol/l and LY294002 3.9 µmol/l;
dark grey columns, rosiglitazone 4.5 µmol/l and wortmannin 50
nmol/l. *p<0.05
Diabetologia (2009) 52:1112–1121 1115
not inhibited by pretreatment with a PI3K inhibitor
(LY294002 or wortmannin) (Fig. 2c). In both low and high
glucose concentrations, the responses in the presence of
AICAR and LY294002 or wortmannin were still signifi-
cantly different from those of the controls, as tested by
ANOVA (Fig. 2c). Consistently, AICAR stimulated Thr172
phosphorylation of the α subunit of AMPK (Fig. 2d) and its
kinase activity (Fig. 2e), which were not inhibited by
pretreatment with the PI3K inhibitor LY294002.
Rosiglitazone inhibits KATP channels through a PI3K-
dependent AMPK signalling pathway The effects of rosi-
glitazone and AICAR on IKATP were examined in primary
cultures of rat islet cells. The holding currents at a
membrane potential of −40 mV were recorded continuously
in the absence or presence of the indicated treatments
(Fig. 3a). Because the experimental conditions reached a
steady state, a ramp voltage protocol (with slope 80 V/s) was
employed to examine the currents elicited from −80 mV to
0 mV (Fig. 3a) and to construct the current–voltage curves in
response to the respective treatments (Fig. 3b). Figure 3a
showed that IKATP was gradually activated and developed to
steady amplitude after intracellular dialysis in a low ATP
condition; the effect was completely abolished by glibencla-
mide. Rosiglitazone significantly inhibited glibenclamide-
sensitive IKATP, but did not alter the residual currents in the
presence of glibenclamide. When the cells were pretreated
with 10 μmol/l LY294002 for 5 min before addition of
rosiglitazone, the inhibitory effect of rosiglitazone on the
IKATP was abolished (Fig. 3c, d), whereas inhibition at a high
glucose concentration (16.7 mmol/l) was not affected
(Fig. 3c, d)
Figure 4 shows the effect of AMPK activation by AICAR
on IKATP in the absence or presence of LY294002. AICAR
inhibited IKATP (Fig. 4a, b), and the effect was unaffected by
LY294002 (Fig. 4c, d).
Both rosiglitazone and AICAR phosphorylate the Ser385 of
the Kir6.2 subunit of the KATP channel in rat islets Accord-
ing to the proteomic professional website (ExPASY
proteomic server, http://tw.expasy.org, accessed 4 January
2006), a FSIS385-containing motif (KFSISPDSLS, amino
acids 381–390 of the Kir6.2 subunit of the KATP channel)
might be a potential AMPK phosphorylation site.
Using immunoprecipitation with anti-Kir6.2 antibodies
followed by immunoblotting with anti-phospho-Ser385
Kir6.2 antibodies, we found that rosiglitazone stimulated
Ser385 phosphorylation of the Kir6.2 subunit (Fig. 5a).
Rosiglitazone-stimulated Ser385 phosphorylation was
inhibited by the AMPK inhibitor compound C and the
PI3K inhibitor LY294002 (Fig. 5a, b). The AMPK activator
AICAR also stimulated Ser385 phosphorylation of the
Kir6.2 subunit (Fig. 5c). We used the FSIS385-containing
Fig. 2 Effect of AICAR on insulin secretion and AMPK activity.
In pancreatic perfusion experiments (see Methods), an equilibration
period of 15 min preceded time 0. a After a baseline period of
10 min AICAR (50 µmol/l) was administered for 30 min. Black
circles, basal control group; white circles, AICAR 50 µmol/l. b Glucose
(Glu; 10 mmol/l) with or without AICAR (50 µmol/l) was
administered for 30 min, followed by perfusion with basal medium.
Horizontal line indicates the presence of AICAR. Values are mean
and SE (n=4). Black circles, basal control group; white circles,
AICAR 50 µmol/l in the presence of glucose 10 mmol/l; black
triangles, glucose 10 mmol/l. c Insulin secretory response in the
absence or presence of AICAR (50 µmol/l) and/or LY294002
(3.9 µmol/l) and wortmannin (50 nmol/l) in low (3.3 mmol/l) and
high (16.7 mmol/l) glucose in MIN6 cells. Data are relative insulin
responses (mean % and SE [bar]) compared with that in glucose
3.3 mM (100% as referent) (n=4). White columns, control, black
columns, AICAR 50 µmol/l, light grey columns, AICAR 50 µmol/l and
LY294002 3.9 µmol/l; dark grey columns, AICAR 50 µmol/l and
wortmannin 50 nmol/l. *p<0.05. d Western blot with anti-AMPK
and anti-Thr172-phospho-AMPK antibodies in the absence or
presence of AICAR (50 µmol/l) and/or LY294002 (3.9 µmol/l) in
low (3.3 mmol/l) and high (16.7 mmol/l) glucose in MIN6 cells.
pAMPK/AMPK density relative to that in glucose 3.3 mmol/l is
shown below (n=3). White columns, control; black columns, AICAR
50 μmol/l; light grey columns, AICAR 50 μmol/l and LY294002
3.9 μmol/l. *p<0.05, non-parametric analysis. e AMPK enzyme
activity in the absence or presence of AICAR (50 μmol/l) and/or
LY294002 (3.9 μmol/l) in low (3.3 mmol/l) and high (16.7 mmol/l)
glucose in MIN6 cells. Data are relative AMPK activities (mean %
and SE [bar]) compared with that in glucose 3.3 mmol/l (100% as
referent) (n=4). The experimental condition for each column is the
same as that for the corresponding column in d
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peptide as a substrate in the AMPK kinase assay and found
that AICAR stimulated a threefold increase in the phos-
phorylation of the FSIS385-containing peptide of the Kir6.2
subunit at both low and high glucose concentrations
(Fig. 5d). Consistently, rosiglitazone also potentiated the
effect of AMPK on Ser385 phosphorylation four- to sixfold,
and this phosphorylation was blocked by approximately
50% by treatment of cells with the AMPK inhibitor
compound C (Fig. 5e). In further experiments, silencing
the expression of AMPK resulted in abolishment of Ser385
phosphorylation of Kir6.2 and insulin secretion in RINm5F
rat insulinoma cells (ESM Fig. 2a–c).
Replacing Ser385 with Ala in the Kir6.2 subunit abolishes
rosiglitazone- and AICAR-stimulated depolarisation of
membrane potential in RINm5F cells Flow cytometric
measurement of the change in membrane potential was
employed to examine differences in pharmacological
responses to rosiglitazone and AICAR in RINm5F cells
transfected with either wild-type Kir6.2 or the Ser385Ala
mutant of the Kir6.2 subunit. Cells with high FL1 signal
were identified as transfected cells for the expression of
EGFP. RINm5F cells were incubated in KRB solutions
containing DiBCA4(5) 400 nmol/l to measure the change in
membrane potential from the FL2 signal. Figure 6b−d
shows that the geometric mean of FL2 was increased after
exposure to glibenclamide, rosiglitazone or AICAR in the
control group (no transfection). In RINm5F cells trans-
fected with either wild-type Kir6.2 or Ser385Ala mutant
Kir6.2, the FL2 signal gated from the same cells in either
the R1 or the R2 region of FL1 (Fig. 6e & j) was used to
measure the changes in membrane potential in response to
the indicated treatments. The membrane potential was
significantly depolarised by adding rosiglitazone and
AICAR in RINm5F cells transfected with the wild-type
human Kir6.2 subunit (Fig. 6h & i), but not in cells
transfected with the Ser385Ala mutant Kir6.2 subunit
(Fig. 6m & n). Glibenclamide significantly depolarised the
Fig. 3 Rosiglitazone-induced inhibition of KATP channel current in rat
islets is mediated by PI3K. a Currents at −40 mV in response to the
respective treatment were recorded continuously, and ramp currents
[indicated as (1)–(6)]were elicited from −80 to 0 mV with slope 80 V/s.
The cell was bathed in external solution containing glucose
3.3 mmol/l. IKATP was gradually activated and reached a steady
amplitude after intracellular dialysis in low ATP (ATP 0.3 mmol/l,
ADP 0.3 mmol/l, EGTA 11 mmol/l, CaCl2 1 mmol/l). (1), break-in;
(2), IKATP at steady state; (3), treatment with rosiglitazone (RSG)
9 µmol/l for 5 min; (4), after washing; (5), treatment with
glibenclamide 30 µmol/l to block IKATP; (6), after rosiglitazone
9 µmol/l for 5 min. Zero current on the vertical scale bar indicates
the baseline of zero current. I(A/F), current density of KATP channel.
b Current–voltage curves for ramp currents elicited in a. c LY294002
(10 µmol/l) pretreatment abolished the inhibitory effect of rosiglita-
zone at −40 mV and the ramp currents elicited with the same protocol
as in a. IKATP was decreased after exposure to glucose 16.7 mmol/l.
d K+ current density at −40 mV in response to rosiglitazone (RSG;
9 µmol/l) in the absence or presence of LY294002 (10 µmol/l)
pretreatment. Significant difference between the presence and absence
of LY294002 pretreatment (n=5, *p<0.05, Student’s t test). Signifi-
cant inhibition of current by rosiglitazone under control condition;
n=5, †p<0.05, paired t test. Black columns, control; white columns,
LY294002 10 µmol/l. (−) indicates the absence of rosiglitazone;
(+) indicates the presence of rosiglitazone
Fig. 4 Inhibition of KATP channel current by AMPK activator AICAR
in rat islets is independent of PI3K activity. a Effect of AICAR on
currents at −40 mV and ramp currents [indicated as (1)–(3)] elicited
from −80 mV to 0 mV with slope 80 V/s. The cell was bathed in
solution containing glucose 3.3 mmol/l. IKATP was gradually activated
and reached a steady amplitude after intracellular dialysis with low
ATP (ATP 0.3 mmol/l, ADP 0.3 mmol/l, EGTA 11 mmol/l/CaCl2
1 mmol/l). (1), break-in; (2), IKATP developed to a steady state
condition; (3), after treatment with AICAR 100 µmol/l for 5 min. The
zero current was indicated at the vertical scale bar. b Current–voltage
curves of the ramp currents elicited in a. c Effect of LY294002 (LY;
10 µmol/l) pretreatment on the inhibitory effect of AICAR in the
currents at −40 mV and ramp currents elicited with the same protocol
as that used in panel a. d K+ current density at −40 mV in response to
AICAR (100 µmol/l) with (+) or without (−) LY294002 (10 µmol/l)
pretreatment. Black columns, control; white columns, AICAR
100 µmol/l. *p<0.05, control vs AICAR; n=4, Student’s t test
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membrane potential of RINm5F cells transfected with
either the wild-type Kir6.2 subunit or the Ser385Ala mutant
of Kir6.2 (Fig. 6g & l). The percentage increments,
compared with controls, in different experimental models
are shown in Fig. 6o.
Discussion
In this study we provide the first evidence showing the role
of AMPK in rosiglitazone-induced and PI3K-dependent
insulin secretion in pancreatic beta cells. The results also
indicate that AMPK-mediated Ser385 phosphorylation of the
Kir6.2 subunit of the KATP channel is critical in modulating
KATP channel activity.
Previously, we used an isolated perfused pancreas
preparation to demonstrate that rosiglitazone acutely stim-
ulates insulin secretion at either a basal or a high glucose
level [15]. More interestingly, both first- and second-phase
insulin secretion induced by high glucose was potentiated
by rosiglitazone in a PI3K-dependent manner [15]. Thia-
zolidinediones have been shown to activate AMPK in
various tissues [28–30], and we also found that rosiglita-
zone acutely stimulates Thr172 phosphorylation of the
α subunit of AMPK, which leads to a two- to fourfold
increase in enzyme activity of AMPK in pancreatic beta
cells. These effects were abolished by LY294002 and
wortmannin, suggesting that PI3K is an upstream regulator
of AMPK activation. A similar pathway has been reported
in bovine aortic endothelial cells [31].
The activity of membrane KATP channels is decreased by
the increased intracellular ATP/ADP ratio that occurs
during the physiological response to glucose stimulation
[20]. Certain pharmacological agents that increase insulin
secretion, such as sulfonylureas and meglitinides, block
KATP channel activity by binding directly to the SUR1
subunit, and lead to depolarisation of the membrane
potential; this depolarisation results in opening of voltage-
dependent calcium channels, which leads to elevation of
intracellular calcium levels and ultimately stimulates insulin
secretion [32, 33]. Although thiazolidinediones have been
shown to stimulate insulin secretion in insulin-secreting
cells [13, 14], the pathway leading to closure of KATP
channels is not clear. Using patch clamp studies, we
showed that rosiglitazone acutely blocks KATP channel
activity, an effect dependent on PI3 kinase activity. In
contrast, glucose-induced closure of KATP channels is
independent of PI3 kinase activity. These data are consis-
tent with our previous findings showing that rosiglitazone-
stimulated insulin secretion is blocked by the PI3K
inhibitor LY294002, whereas glucose-stimulated insulin
secretion is not affected by LY294002 [15].
Protein phosphorylation is an important biological
process that is a possible mechanism for the regulation of
the activities of ion channels and a wide variety of cellular
functions [34]. In addition to being regulated by various
nucleotides, the activity of the KATP channel can be further
modulated by phosphorylation events induced by activated
protein kinase A and protein kinase C [21, 22]. These
phosphorylation events occur at selective amino acid
Fig. 5 Phosphorylation of Ser385 of the Kir6.2 subunit of the KATP
channel is stimulated by rosiglitazone through PI3K-dependent
AMPK activation. a Immunoprecipitation with anti-Kir6.2 peptide
antibody followed by western blotting with anti-phosphoserine385
Kir6.2 peptide antibody or anti-Kir6.2 peptide antibody in the absence
or presence of rosiglitazone (RSG; 9 µmol/l) and/or compound C
(C.C; 40 µmol/l, pretreatment for 1 h) in low (3.3 mmol/l) and high
(16.7 mmol/l) glucose in rat islets. b Immunoprecipitation with anti-
Kir6.2 peptide antibody followed by western blotting with anti-
phosphoserine385 Kir6.2 peptide antibody or anti-Kir6.2 peptide
antibody in the absence or presence of rosiglitazone (9 µmol/l) and/
or pretreatment with different concentrations of LY294002 (10 or
50 µmol/l). c Immunoprecipitation with anti-Kir6.2 peptide antibody
followed by western blotting with anti-phosphoserine385 Kir6.2
peptide antibody or anti-Kir6.2 peptide antibody in the absence or
presence of AICAR (100 µmol/l) in rat islets. d Phosphorylation of the
FSIS-containing peptide of Kir6.2 in the i.p. AMPK kinase assay from
rat islets in the absence or presence of AICAR (100 µmol/l). White
columns, control; black columns, AICAR 100 µmol/l. Glu, glucose.
e Phosphorylation of the FSIS-containing peptide of Kir6.2 in the
immunoprecipitated AMPK kinase assay from rat islets in the absence
or presence of rosiglitazone (9 µmol/l) and/or compound C (40 µmol/l,
pretreatment for 1 h) in rat islets. Data are relative AMPK activities (mean
% and SE [bar]) comparedwith that in glucose (Glu) 3.3mmol/l (100% as
referent). White columns, control; black columns, rosiglitazone 9 µmol/l;
light grey columns, rosiglitazone 9 µmol/l and compound C 40 µmol/l;
dark grey columns, compound C 40 µmol/l. *p<0.05, control vs
treatment; n=4, Student’s t test
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residues within specific peptide motifs. These phosphory-
lation events lead to enhanced channel activity. In this
study, we demonstrated that the Ser385 residue within the
peptide motif of KFSISPDSLS was phosphorylated by
activation of AMPK. On the other hand, silencing the
α subunit of AMPK inhibited rosiglitazone-stimulated
phosphorylation of Ser385 of the Kir6.2 subunit and
subsequent insulin secretion, indicating that rosiglitazone-
stimulated insulin secretion acts at least partly through an
AMPK-dependent pathway. To establish unequivocally the
role of Ser385 in the Kir6.2 subunit, we demonstrated that
both rosiglitazone- and AICAR-induced depolarisation of
membrane potential in RINm5F cells was markedly attenu-
ated in cells overexpressing the Ser385Ala mutant of the
Kir6.2 subunit. These data suggest that Ser385 phosphoryla-
tion is essential and necessary for rosiglitazone-stimulated
insulin secretion. It is worthy of note that the 15 amino acid
peptide sequence (AKAKPRFSISPDSLS) at the C terminus
of Kir6.2 is highly conserved across different species,
suggesting that this region has an important biological
function in the regulation of KATP channel activity.
The effects of thiazolidinediones on pancreatic beta cell
function are not consistent among different reports, mostly
because of differences in experimental design [4, 13, 14,
35–42]. More studies need to be done to substantiate our
understanding of the signalling pathway involved in
rosiglitazone-induced insulin secretion through regulation
of KATP channel activity by AMPK. For example, an
Fig. 7 Pathways leading to insulin release in pancreatic beta cells.
ER, endoplasmic reticulum; RSG, rosiglitazone; SG, secretory
granules; VDCC, voltage-dependent calcium channel. The pathway
from glucose-stimulated insulin secretion is depicted according to
Straub and Sharp [20]
Fig. 6 Depolarisation of membrane potentials by either rosiglitazone
or AICAR in non-transfected and wild-type Kir6.2-transfected
RINm5F cells but not in Ser385Ala Kir6.2 mutant-transfected
RINm5F cells. Membrane potential was measured by flow cytometry
and geometric means of FL2 fluorescence were compared. a–d FL2
fluorescence in non-transfected RINm5F cells in the absence (a) or
presence of glibenclamide (b; 30 µmol/l), rosiglitazone (c; 9 µmol/l)
and AICAR (d; 300 µmol/l). e–i FL2 fluorescence in wild-type Kir6.2
transfected RINm5F cells in the absence (f) or presence of
glibenclamide (g; 30 µmol/l), rosiglitazone (h; 9 µmol/l) and AICAR
(i; 300 µmol/l). The FL2 signal gated from the same cells in the R1
region (e; purple, non-transfected cells; green, cells transfected with
Kir6.2 wild-type) of FL1 was used to measure the change in
membrane potential in response to treatment. R1, the region wherein
EGFP-positive cells contain higher FL1 intensity. j–n FL2 fluores-
cence in Ser385Ala Kir6.2 mutant-transfected RINm5F cells in the
absence (k) or presence of glibenclamide (l; 30 µmol/l), rosiglitazone
(m; 9 µmol/l) and AICAR (n; 300 µmol/l). The FL2 signal gated from
the same cells in the R2 region (j; purple, non-transfected cells; red,
cells transfected with Ser385Ala Kir6.2 mutant) of FL1 was used to
measure the change in membrane potential in response to treatment.
R2, the region wherein EGFP-positive cells contain higher FL1
intensity. FL1-H: FL1 histogram; FL2-H: FL2 histogram. o Percentage
increments compared with controls in different cell condition. White
columns, control; black columns, glibenclamide 30 µmol/l; light grey
columns, rosiglitazone 9 µmol/l; dark grey columns, AICAR 300 µmol/l.
*p<0.05, n=4
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attempt should be made to replicate our results using islets
from AMPK−/− mice to verify the role of this important
molecule in physiological and pharmacological stimulation
of insulin secretion. Previous reports have shown different
relationships between the activation of AMPK and glucose-
stimulated insulin secretion [16–18, 43–45]. However,
these differences may be explained in large part by the
different glucose concentrations and experimental systems
employed in the different studies. Forced increases in
AMPK activity by AICAR treatment or by adenoviral
overexpression of a truncated, constitutively active form of
the enzyme (AMPKα1.T172D) have been shown to block
glucose-stimulated insulin secretion in MIN6 cells and
isolated rat islets [44] and lead to apoptosis of beta cells
[46]. By contrast, inactivation of AMPK by expression of a
dominant-negative form of the enzyme (AMPKα1.D157A)
increases insulin secretion at a low glucose concentration
(3 mmol/l) but not at a high glucose concentration [44]. By
the use of another pharmacological agent, metformin,
which has been shown to stimulate AMPK activation
[45], results were even more conflicting when metformin
was used alone [45] or in combination of glibenclamide
[47]. In the present study, we found that short-term
treatment with the AMPK activator AICAR stimulated
insulin secretion, an effect that was independent of glucose
concentration and was mediated by inhibition of KATP
channel activity. Stimulation of insulin secretion in
response to AMPK activation by AICAR at physiological
glucose concentrations [16–18, 48] is in agreement with our
present findings.
In conclusion, we report that rosiglitazone-stimulated insulin
secretion occurs through PI3K-dependent activation of AMPK
and subsequent inhibition of the KATP channel current (see
model in Fig. 7). KATP channel activity is probably regulated
by phosphorylation of the Ser385 residue of the Kir6.2 subunit
by activation of AMPK in pancreatic beta cells.
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